Biomea Fusion was set to release early results for its investigational obesity candidate on October 13, with shares at $1.44 in premarket trading.
Recap by typeshit. Full story at RTTNews.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Mounjaro held 86.7% of Korea's GLP-1 weight loss market in June, and Hanmi's homegrown Eppe was just approved in five strengths.
The pact adds to a busy run of China deals for Roche and is a bet on medicines that lower visceral fat.
Loading…